RELMADA THERAPEUTICS, INC. - 8-K Filing
Relmada Therapeutics reported Q1 2026 financial results with a net loss of $19.1 million (or $0.22 per share) compared to $17.6 million in the same period last year, and disclosed cash balances of $234.0 million as of March 31, 2026, which is expected to fund operations through 2029. The company announced positive Phase 2 data for NDV-01 showing a durable complete response rate of 76% at 12 months in high-risk non-muscle invasive bladder cancer patients and plans to initiate the Phase 3 RESCUE program mid-2026. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $RLMD